SCHEMBL7091315

SCHEMBL7091315

CSc1ccc(-c2c(C)cc(C)cc2C(O)(C(=O)c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.35
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
KIF11 P52732 1/20 0.33
ALDH1A1 P00352 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LMNA P02545 2/20 0.33
KMT2A Q03164 4/20 0.33
TSHR P16473 1/20 0.33
CES1 P23141 1/20 0.33
PTGS2 P35354 3/20 0.32
HAO1 Q9UJM8 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
MEN1 O00255 3/20 0.32
MAPT P10636 2/20 0.32
RAB9A P51151 2/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
NSD2 O96028 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7090214 0.82 CES1 (0.34) CYP2C9AKR1C3AKR1C2AKR1C1KIF11
SCHEMBL7090546 0.77 CES1 (0.36) CYP2C9AKR1C3AKR1C2AKR1C1KIF11
SCHEMBL7090145 0.76 PLK4 (0.37) CYP2C9ALDH1A1SMN1; SMN2KMT2ACES1
SCHEMBL7089474 0.75 PPARG (0.39) CYP2C9AKR1C3AKR1C2AKR1C1KIF11
SCHEMBL7085133 0.75 CES1 (0.36) CYP2C9AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL7087777 0.73 NOX1 (0.36) CYP2C9AKR1C3AKR1C2AKR1C1KIF11
SCHEMBL7090552 0.69 CES2 (0.37) AKR1C3AKR1C2AKR1C1CES1PTGS2
SCHEMBL7089416 0.68 CYP2C9 (0.37) CYP2C9ALDH1A1SMN1; SMN2KMT2ACES1
SCHEMBL7089413 0.68 DDR1 (0.35) CYP2C9ALDH1A1LMNACES1
SCHEMBL14002002 0.67 CES1 (0.52) CYP2C9KIF11ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 CYP2C9 529/4885AKR1C3 368/4885AKR1C2 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.